“…Acute lymphoblastic leukaemia (ALL) occurs with 24-fold greater incidence (Hasle et al, 2000) in children with Down syndrome (DS) (Online Mendelian Inheritance in Man [OMIM] number 190685) and poses specific challenges during treatment (Whitlock, 2006;Maloney, 2011). Survival of ALL in children with DS (DS-ALL) is lower than in the general paediatric population (Bassal et al, 2005;Whitlock, 2006;Buitenkamp et al, 2011). This inferior success rate of primary ALL therapy in children with DS has not been attributable to a specific disease mechanism, such as increased expression of the cytokine receptor CRLF2 (Mullighan et al, 2009;Russell et al, 2009;Harvey et al, 2010;Hertzberg et al, 2010) and activating mutations of the gene encoding the signal transducer JAK2 (Gaikwad et al, 2009;Kearney et al, 2009;Harvey et al, 2010;Hertzberg et al, 2010) in the blasts of DS-ALL.…”